Out of these five targets, FGFR2 (targeted by nintedanib, Fig. 3A) and JAK3 (targeted by momelotinib, Fig. 3G) have a well described role in cancer and they are both annotated as hallmark oncogenes in COSMIC. Here, FGFR2 is linked to cancer.